Certificate under Regulation 74(5) of SEBI(Depository and participants)Regulations,2018 for the Quarter and year ended 31st March 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Welcure Drugs & Pharmaceuticals has submitted a routine compliance certificate to BSE from its Registrar and Transfer Agent (Skyline Financial Services) covering the quarter ended 31 March 2025. The certificate confirms that physical share certificates received from shareholders for dematerialization were processed and the depository was recorded as the registered owner within the 15-day SEBI deadline. During Q4 FY25, a total of 21 demat requests were processed — 4,700 shares via CDSL and 1,500 shares via NSDL. Out of these, 400 NSDL shares (2 requests) were rejected while the remaining 5,800 shares were successfully dematerialized. No rematerialization requests were received. The director Suraj Chagan Solanki signed the filing on 10 April 2025.
This is a routine regulatory compliance filing with no material impact on the company's financials or stock price. It only reflects small-scale shareholder activity of converting physical shares into electronic (demat) form, which is administrative housekeeping rather than any business event.